Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Video: Tar Heels in DC - Capitol Tour With Elizabeth Adkins
North Carolina alumna Elizabeth Adkins (Class of 2018) serves as Chief of Staff for Congresswoman Valerie Foushee. Follow along as Adkins takes us on a...
Wed Jul 22, 2026

New and incoming restaurants add to Chapel Hill's vibrant food scene
In the past year, Chapel Hill has seen its restaurant scene expand, and its offerings will continue to grow, with a variety of new spots,...
Mon Jul 20, 2026

Video: Tar Heels in DC - Smithsonian’s National Museum of American History with Frank Blazich
UNC alumnus Frank Blazich (Class of 2004), modern military history curator at the Smithsonian’s National Museum of American History, gives us a tour of the...
Mon Jul 20, 2026

Video: Tar Heels in DC - CNBC newsroom with Megan Cassella
UNC alumna Megan Cassella (class of 2015), Washington Correspondent for CNBC, gives us a tour of the newsroom and studios she works in and discusses...
Sun Jul 19, 2026